Nanopharm Limited has announced an agreement with US-based Sciarra Laboratories that will pair Nanopharm’s SmartTrack OINDP development services with Sciarra’s GMP metered dose inhaler manufacturing services.
Together, Nanopharm and Sciarra will comprise a CDMO with more than 30,000 square feet of research and manufacturing space, which the companies say “offers for the first time a truly ‘one stop’ shop for clients committed to the development and manufacture of MDI drug products.”
Nanopharm CEP Jag Shur CEO commented, “Our strategic alliance with Sciarra marks a significant milestone for Nanopharm, as we now focus on translating our SmartTrack development platform to enable manufacture of MDIs from early phase development through to commercial manufacture.”
Nanopharm Founder and Chief Scientific Officer Robert Price added, “Our collaboration with Sciarra will enable us to provide science-led development and manufacture of MDIs, which will ultimately allow us to help our clients by de-risking their program and moving it swiftly into the pivotal phases of the drug product development value-chain.”
Sciarra Laboratories CEO Christopher Sciarra said, “We are excited at the prospect of working with Nanopharm in this key area and we are now well placed to drive the considerable value that exists for our clients. The combination of the state of art analytical and manufacturing capabilities for MDIs, will help us to accelerate the development programs for our clients”
Read the Nanopharm and Sciarra Laboratories press release.
